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INTRODUCTION FOR ANNUAL REPORT 1991
The Cancer Committee continues to function as a multi-disciplinary committee overseeing and monitoring the Oncology Program of St. Luke’s Medical
Center. In that capacity, this year the committee has encouraged and supported continued head and neck cancer screenings, prostate cancer screenings,
and skin cancer screenings. In addition, Rehabilitation Medicine has devel
oped a cancer rehabilitation interest group with a resultant increase in their
services to oncology patients. All 2$ beds of the Oncology Unit were opened
this past March.
Monitoring activities of the Cancer Committee included reporting of the
short-term and long-term studies completed through the American College of
Surgeons on ovarian, cervical and colorectal cancer. In-house studies on soft
tissue sarcomas, prostate cancer, and multiple myeloma were performed and
discussed.

Marcia J.S.
Richards, M.D.

Educational efforts for the medical staff included Security Savings and Loan
Cancer Lectureship Series and public education forums on colon, breast, skin,
ovarian, and cervical malignancies. Continued supportive association with
the Vince Lombardi Golf Classic has facilitated research activities in the area
of oncology, and provided resources for patient education, early detection,
and prevention programs.
A new event, the Vince Lombardi Award of Excellence Dinner Ball, was held
early in 1991 with the support of the Vince Lombardi Golf Classic. Once
again, the Vince Lombardi Golf classic was a success. Activities which were
coordinated through the Vince Lombardi Cancer Clinic continued to grow.
These activities included the Hotline, the Newsletter, and the Patient
Education Series.
A new support group for patients with ovarian cancer was developed at
St. Luke’s Medical Center in 1991 in response to a need by the community.
St. Luke’s also continued its interaction and activity with the Cancer Society
by co-sponsoring the American Cancer Society’s Bike-a-thon.
The Department of Radiation Oncology experienced some growth and
moved into a partial expansion mode in order to add a third linear accelera
tor for patient treatment.
Grants were made available through the Schroeder Chair to facilitate the start
of new programs in oncology. With input from the Cancer Committee,
Oncology Education programs were added to the educational TV programming made available to St. Luke’s patients.
In August of 1991, Dr. Stephen Hazelrigg, from the Department of
Cardiothoracic Surgery, directed a surgical lung cancer symposium.
For most of the year we functioned without a Director for the Cancer
Program, but we were pleased to welcome Nancy A. Nowak to that position
during the latter part of 1991.
Again, the Cancer Program at St. Luke’s Medical Center exhibited growth in
patient services with an increase in patient numbers, new programmatic
development in the area of oncology, and continued cancer education of the
medical staff and community.

Marcia J.S. Richards, M.D.
Chairperson, Cancer Committee
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EPIDEMIOLOGY OF LUNG CANCER

According to Cancer Facts &
Figures 1991:
-

In 1 987, for the first time in over forty years,
more women died of lung cancer than breast
cancer, which had, until that time, been the
major cause of cancer death in women. The
incidence rate had been increasing steadily in
men and women for several decades but had
begun to decline in men in the latter part of
the 1980’s. The incidence rate in women
though has continued to increase. This trend
appears to be reflected in the following
Age/Sex distribution comparing patients diag
nosed and treated for lung cancer here at St.
Luke’s Medical Center in 1 986 and in 1991.
In 1 986, of the 1 60 lung cancer patients,
69.4% were male and 30.6% were female.
In comparison, for the 1 77 lung cancer
patients in 1991, only 55.1% were male and
44.9% were female. This presents a contin
ued increase in female incidence of lung cancer as suggested by the American Cancer
Society.

In 1992, in the United States, an estimated 168,000 individuals will be diag-.
nosed with cancer of the lung and of these 146,000 will die of the disease.
of those diagnosed, 2,800 will reside in Wisconsin. The incidence rate of
lung cancer had been steadily increasing in both men and women for several
decades, but more recently is starting to decline in men. Unfortunately,
women are still seeing the effects of their most recent increase in tobacco use.
Regrettably, the majority of these deaths are preventible since most lung cancers are related to tobacco use, in particular cigarette smoking. In addition,
certain industrial substances, such as arsenic, organic chemicals, and asbestos
may increase the risk of lung cancer particularly in smokers. Radiation
exposure medically, occupationally, or environmentally also increases the
risk of lung cancer. Regrettably some individuals also develop this malignan
cy from second hand smoke.
Increasing evidence also supports an increased risk in certain individuals for
developing lung cancer when exposed to carcinogenic agents. Genetic factors
predisposing to an increased risk of lung cancer may be related to certain
metabolic pathways involving carcinogenic environmental agents, and the
presence of certain proto-oncogenes and/or autocrine growth factors.
Protective factors may also play a favorable role in decreasing the risk of lung
cancer with adequate levels of beta-carotene, vitamin A and E and selenium.
These findings have prompted early chemotherapy prevention trials in persons at high risk.
Since the overall cure rate for cancer of the lung is about 10%, any gains that
are made in prevention will have a large impact in terms of total lives saved.
of the preventative resources, a reduction in tobacco usage will result in the
greatest decrease in morbidity and/or mortality from this malignancy which
is the number one cause of death from cancer in both men and women.
Marcia J.S. Richards, M.D.

1986 LUNG CANCER CASES DIAGNOSED 1991 LUNG CANCER CASES DIAGNOSED
BY AGE AND SEX
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ADVANCES IN SMOKING CESSATION
Smoking cessation is extremely important in the prevention of cancer. It is
estimated that changes in lifestyle could reduce the incidence of cancer by
37%. This is particularly important to those individuals who have a family
history of cancer or exposure to carcinogens in their home or work environment.
The treatment plan for helping smokers to become smoke free has changed.
It now takes into account that smokers have physical as well as behavioral
addictions to tobacco. Nicotine is the toxin present in cigarette smoke that is
responsible for the chemical addiction. Smokers self-administer nicotine with
each cigarette to avoid the withdrawal symptoms of craving, irritability, frus
tration, anger, anxiety, difficulty concentrating, andlor restlessness.
Nicotine replacement has been used in smoking cessation programs for some
time in the form of Nicorette gum. This gum was helpful but required proper instruction on its use and did not taste good. The newest form of nicotine
delivery is the nicotine patch. There are many brands
available. Smokers considering the patch need to consult
their doctors to determine whether the patch is safe for
them and which patch would be best tolerated. Pregnant
women or nursing mothers are not candidates for the patch
because of the potential harm to the fetus or infant. The
potential side effects of the patch are: skin irritation,
headache, dizziness, upset stomach, drooling, vomiting,
diarrhea, cold sweats, blurred vision, difficulty with hearing, mental confusion, weakness, insomnia, and nightmares. These symptoms occur most often if the user has
been smoking while wearing the patch or if the strength of
the patch is too high for the user. In addition, there has
been an increased incidence of heart attack reported in
smokers who have been smoking while wearing the nico
tine patch. Once a cigarette is lit, the patch must come off
and the smoker must determine whether they are truly
committed to quitting smoking before the patch is reapplied.

Becky Poga car,
RN

The most important aspect of quitting smoking is learning
new coping skills for the situations that trigger the smoking
behavior. The greatest success with the patch has been
demonstrated in cases where the patch has been used in
conjunction with a smoking cessation program.
In summary, quitting smoking takes commitment. There is
no completely “painless” method although nicotine
replacement can reduce cravings and withdrawal symp
toms. Learning to live without tobacco is the key to continued success when the patch comes off. Hard work does
pay off. Becoming a nonsmoker means taking control
back from that three inch stick of tobacco.

Becky Pogacar, RN
Clinical Coordinator of Pulmonary Rehabilitation
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ROLE OF ThE FAMThY PHYSICIAN IN LUNG CANCER
The mortality rate from cancer, which is the second most common cause of•
death in adult Americans, has increased during the past several decades, all
scientific advancements notwithstanding. Lung cancer, which has shown a
dramatic and alarming increase, is largely responsible for the sad statistics,
and it remains the epitome of a successful malignant disease, accounting for
the highest number of annual cancer-related deaths. Ironically, cancer of the
lung is among the most preventable of all cancers in that a causative agent
smoking has been recognized as the most important avoidable cause of
death in our society.
-

-

Herbert F.
Laufenburg, M.D.

The family physician, usually the physician of first encounter is in a unique
position. His office serves a dual role when it comes to cancer. It is not only
a cancer diagnostic center providing early screening and detection, but just as
important, a cancer prevention center providing advise and education to
patients about cancer. This becomes vitally important when it comes to lung
cancer as it has not proven amenable to screening procedures.
Preventive strategies and techniques, however, do work and it is the family
physician who takes the initiative to deliver the important message on the
hazards of smoking and tobacco, thus making the patient and public aware
of the heavy toll exacted by smoking. The caring family physician will
expend efforts at behavioral modification for his/her patients in all health
care matters and will direct efforts at 1 ) counseling patients to quit smoking,
2) offering advise and assistance in stopping, and 3) providing encouragement, reinforcement and support. The family physician will always herald a
high index of suspicion when the patient presents with the early warning
signs that point to the possibility of malignant lung disease persistent cough,
blood streaked sputum, recurrent bronchitis, unresolving pneumonia and
general systemic complaints such as weight loss, anorexia, fatigue, weakness
and fever.
-

While the prognosis for lung cancer remains dismal, the family physician will
direct concerted efforts at early detection and prevention. Prevention, after
all, is less costly, medically far superior and can be a life saver.
Herbert F. Laufenburg, M.D.
According to CA A Cancer Journal for
Clinicians: For a group ofpatients diag
nosed between 1981 and 1987, 18% of the
lung cancer patients are diagnosed at a
local stage, 3 1 % are diagnosed at a regiona! stage, and 39% are diagnosed at a dis
tant stage. The graphs below, for St.
Luke’s Medical Center patients, reveal an
increase in the percent ofpatients being
diagnosed at a regional stage in 1 991 ver
sus 1986. Our rates for other stages of dis
ease at diagnosis appear to be similar to
those national rates published in the above
mentioned journal.

General Summary Stage at Diagnosis
Lung Cancer 1 986 vs. 1991

-

-

1986

UNKNOWN 11%

1991
LOCAL 25%

REGIONAL 29%
DISTANT 35%

REGIONAL 36%

L1.111
DISTANT 38%
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UNKNOWN 2%

LOCAL 24%

TRADONAL TREATMENT APPROACHES 10 LUNG CANCER
Standard treatment options utilized for lung cancer treatment include surgery,
radiation therapy, and chemotherapy. These modalities may be used alone
or in combination. Physicians must weigh several factors before making
a recommendation of therapy type for lung cancer. These include the
histologic cell type of the tumor, the stage of the tumor and the overall
medical condition of the patient.
Although there are several different types of lung cancer recognized by
pathologists, in general, the treatment options one considers are based on
whether the tumor type is small cell (oat cell) or non-small cell. Small cell
cancers account for 20 percent of lung cancers, and the initial treatment for
this aggressive lesion is always a combination of radiation and chemotherapy.
Paul H. Werner,
Non-small cell tumors in patients who are an acceptable surgical risk are conM.D.
sidered for surgical resection if the tumor is in an early enough stage. The
stage of a cancer is determined by the size and location of the primary tumor
and whether or not spread to lymph nodes
(glands) or other organs (brain, bone or liver)
FIRST COURSE OF TREATMENT
has occurred. Staging techniques involve multiple
ALL STAGES -1986
diagnostic modalities including: history and
physical examination, chest x-ray, blood tests,
TREATMENT
computerized tomography (CAT scan) organ
SURGERY ONLY
scan, bronchoscopy needle biopsy and various
RADIATION ONLY
minor ann major surgical procedures. Tne earnCHEMOTHERAPY ONLY
er the stage at which lungcancer is detected, the
SURGERY & RADIATION
better the chances for achieving a cure.
SURGERY & CHEMO
Unfortunately, almost one-half of patients prePDIATION & CHEMO
senting with lung cancer already have evidence
RADIATION & HORMONES
CHEMO & HORMONES
of distant spread. After further staging, another
4.4
25 to 30 percent will be found to be unsuitable RADCHEMO & HORMONES
RAD,CHEMO
&
SURGERY
•1.9
candidates for operation. Therefore, only 20-25
0.6
RAD,CHEMO,SURG,HORM
percent of patients are surgical candidates.
0.6
.

.

.

.

..

Before surgery is undertaken, the patient must be
evaluated to determine the ability to withstand
the stress of the operation. One must also have
enough reserve lung function to tolerate the
removal of a portion or all of a lung. Depending
on the stage and cell type, the patients that are
not appropriate candidates for surgical treatment
are usually referred for radiation andlor
chemotherapy.

OTHER
SURG, RAD, OTHER
RAD, CHEMO, OTHER

0.6
1.3

13.1

NONE
0

5

10

15

20

25

30

PERCENTAGE OF PATIENTS TREATED

FIRST COURSE OF TREATMENT
ALL STAGES 1991
-

TREATMENT

Paul H. Werner, M.D.

Treatment for primary lung cancer is
determined by the cell type and stage
ofthe cancer. Options for treatment
include surgery, radiation therapy, and
chemotherapy or a combination of the
three. The following treatment distrib
utions show an increase in the use of
radiation therapy in 1 991 as a primary
treatment modality and a decrease in
the use of combined radiation therapy
and chemotherapy in 1991 when com
paredto 1986.
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ThORACIC IMAGING FOR BRONCHOGEMC CARCINOMA

Michael Kehoe,
M.D.

Imaging plays a key role in the diagnosis, staging, and evaluation of treatment regimens for lung carcinoma. The vast majority of cases of lung
cancer are diagnosed on standard chest x-ray, often “routine tests” obtained
for other purposes. Once diagnosed, more exacting and specific modalities,
including computerized tomography, magnetic resonance imaging, and
nuclear medicine studies, are undertaken to evaluate for extent of disease,
helping to direct to appropriate therapeutic regimen. Occasionally, these
higher technology imaging modalities are applied in a specific searching
diagnostic role, such as magnetic resonance scanning of the thorax for
neoplasms in individuals presenting with ectopic Cushing’s Syndrome. In
general, these cross-sectional imaging techniques, however, are not warranted on a screening basis.
Transthoracic needle biopsy, either under ftuoroscopic or CT guidance, has
been performed at St. Lukes’s Medical Center over the past 12 years, allowing a tissue diagnosis with low morbidity and can, at times, obviate the need
for open thoracotomy (Figures 1 and 2). Recently, pre-operative needle
localization for thorascopic lung nodule excision in a manner analogous to
breast biopsy has been undertaken at our institution.
The staging procedure for lung carcinoma has become more directed with
appropriate scans being obtained based on the patient’s tumor histology
and symptomatology, rather than the “shotgun” approach of the past, saying both time and money. CT scanning for treatment planning is an intergral part of radiation therapy for lung carcinoma in the chest. The crosssectional imaging techniques allow more direct measurement of tumor size
to evaluate response to therapy and evaluate the spread of disease.
Thoracic imaging using the various modalities has been and will remain
an intergral part of diagnosis evaluation and treatment for bronchogenic
carcinoma.

Michael Kehoe, M.D.
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LUNG FUNCTION: EFFECT ON TREATMENT OPTIONS
The only cure for lung cancer is surgical resection which will depend upon
cell type, the patient’s overall general medical condition, and extent of dis
ease. Surgery is not indicated when unresectable metastasis are present and
except for a rare exception, when the cell type is a small cell carcinoma. Pre
operative pulmonary function testing can help determine whether patients
with emphysema and chronic bronchitis could tolerate surgery. The most
frequently used test is the spirogram, during which a patient is asked to
exhale as rapidly as possible following a deep inspiration. Most normal peo
pie can exhale 4 liters of air in one second. Patients with chronic lung disease
can still tolerate major surgery if they can exhale only 2 liters in one second.
Additional testing is required to assess surgical risk if the exhaled volume in
one second is less than 2 liters. In suitable candidates, the overall operative
mortality for lung cancer is less than 4 percent and depends upon the extent
of resection. Some carefully chosen lung cancers may become operable after
radiation therapy. Reduced lung function is usually not a limiting factor if
radiation or chemotherapy is needed to control pain, lung collapse or expec
toration of blood. However, radiation can injure the lung. The earliest effect
is inflammation, (radiation pneumonitis) which may progress to scarring
(radiation fibrosis). The overall incidence of these changes is not great but
affected patients usually develop shortness of breath and, to a lesser extent,
an increase in cough and fever. The early
administration of steroids is occasionally
effective treatment but fibrosis is not
reversible. Chemotherapeutic agents may
be toxic to the lung as well but the
incidence is fortunately low. Pulmonary
complications may include collection of
fluid (pulmonary edema), inflammation
(pneumonitis), and scarring (fibrosis).
Damage can be limited by monitoring
with serial pulmonary function tests and
chest x-rays.

Stuart Levy, M.D.

Stuart Levy, M.D.
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LUNG CANCER: ThE ROLE OF MINIMALLY INVASiVE
Surgery remains the primary curative modality in lung cancer. The one stage
pneumonectomy first performed by Dr. Graham in 1933 was at one time
considered the best curative operation for lung cancer. Subsequently, similar
results were obtained with lesser resections and the lobectomy became the
gold standard for localized tumors. Most lung resections utilize a posterolat
eral thoracotomy incision. This incision is well known for the production of
postoperative pain. Recent areas of study in thoracic surgery have included:
methods to lessen this postoperative pain (and therefore decrease pulmonary
complications), better ways to diagnose the indeterminate pulmonary nodule,
and interest in lesser resections for primary lung cancer.
Stephen R.
Hazelrigg, M.D.

The term minimally invasive thoracic surgery refers to an attempt to embrace
less invasive methods of accomplishing the same surgical procedures.
Minimally invasive thoracic surgery encompasses modified thoracic incisions
as well as the recent explosion in endoscopic surgical techniques.
Alterations in thoracic incisions have been attempted as one method of
decreasing pain and morbidity. Several modified thoracotomy incisions
exist, however, most involve the sparing of the large thoracic musculature
instead of the transection of these muscles. Muscle sparing incisions have
demonstrated benefits with respect to early postoperative pain as well as
shoulder girdle strength. Other improvements have included the use of
epidural catheters which have achieved similar success with respect to postoperative pain.
Thoracoscopy or video assisted thoracic surgery (VATS) has emerged as an
exciting new modality. ft has begun to play a role in diagnosing pulmonary
nodules, in staging lung cancer, and in selected cases for definitive resections
for metastatic lung lesions as well as primary lung cancers.
We are frequently presented with patients who have new lung lesions that
require diagnosis. Many of these patients ultimately come to thoracotomy to
achieve this diagnosis. Thoracoscopy has been a welcome alternative for
many patients. Peripheral lung nodules can be resected with small incisions
and no rib retraction. Even deeper lesions have been resected using the
Nd:YAG laser thoracoscopically. Typical hospital stay has been less than 4
days with pain well controlled by oral analgesics. Our experience with the
peripheral lung nodules resected thoracoscopically has been that over 40%
prove to be benign and another 33% have been metastatic. These patients
effectively avoid any need for a thoracotomy incision. For patients with pri
mary lung cancer diagnosed from this wedge resection, a more extensive
resection is recommended. Most of these patients have subsequently undergone thoracotomy and lobectomy.
There is a subset of lung cancer patients who do not have enough pulmonary
reserve to tolerate a lobectomy. For these patients, a wedge resection is a
compromise which still offers a chance for survival. Survival figures on Stage
I peripheral lung cancers have not been significantly different than similar
patients after lobectomy. The main disadvantage of these limited resections
has been a higher incidence of local recurrence. Studies are now underway to
evaluate thoracoscopic wedge resection with the addition of coned down
radiation therapy in an effort to decrease the incidence of local recurrence.
Thoracoscopic lobectomy has been performed but remains experimental.
Although it would appear that the pain is less, the hospital stay has not been
significantly shortened. Other concerns include more operative risk due to
vascular injury and a prolonged time required to perform the lobectomy.
Prospective randomized trials remain in progress to try to answer these
questions.
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SURGERY
Survival in lung cancer is directly related to the stage of the disease. For later
staged cancers, the use of multi-modal therapy is available which combines
surgery with chemotherapy and radiation therapy. We have used thora
coscopy to help stage patients with lung cancer in order to more ideally
design therapy for them. Presently, we know that tumors which spread to
mediastinal lymph nodes carry a poor prognosis with surgical resection
alone. For these patients, experimental studies involving preoperative
chemotherapy and radiation therapy offer some hope of improvement. On
occasion, findings at thoracoscopy reveal that surgery would be inappropri
ate and avoids an unnecessary thoracotomy.
In conclusion, minimally invasive thoracic surgery carries the goal of improv
ing patient comfort and decreasing morbidity. These changes must be
achieved without compromising the cancer operation. Thoracoscopy has
aided in diagnosing nodules and so has helped to avoid thoracotomy for
benign and many metastatic lesions. It offers some advantages for staging in
selected patients. For poorer risk patients, it offers the opportunity for resec
tion of the lung cancer and improves their chance for survival. For many
patients, these minimally invasive techniques have been a great advantage
and we feel fortunate at St. Luke’s to remain a leader on a national level with
respect to these surgical advances. We hope that by offering a better tolerat
ed method of diagnosing lung cancer that we can identify these patients at an
earlier stage and thus improve the five year survival figures.

According to a Professional Education
Publication from the American Cancer
Society, squamous cell carcinomas were at
one time the most frequently noted cell type
of bronchogenic carcinoma in the United
States. In the last decade, data has showed
an increase in the incidence of adenocarcino
ma as the most frequently noted histology.
This is displayed at St. Luke’s Medical
Center in 1986 and 1991 where adenocarci
noma was revealed as the most frequently
found cell type for lung cancer patients at
this facility. The increased incidence of ade
nocarcinoma has been attributed to several
factors, including the increasing frequency of
lung cancer among women, occupational
and environmental carcinogens, and smok
ing. Efforts which have been made toward
early detection and treatment have failed to
reduce lung cancer mortality substantially,
therefore, control of cigarette smoking
remains the single most important measure
for combatting this disease.
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-
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Stephen R. Hazelrigg, M.D.
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LUNG CANCER RESEARCH
At St. Luke’s Medical Center, patients with lung cancer have an opportunity
to participate in a spectrum of research programs. These programs are
designed to provide the best treatment of their disease, while answering ques
tions critical to the care of all future patients.
Stage I: Chemo-Preventjon with 13-cis RA
Patients who have undergone a curative resection of stage I disease are at risk
of developing new unrelated cancers within the lung and upper aero-digestive
tract. These cancers, called second primary tumors, arise as a result of
repeated carcinogejc insult from tobacco use. They arise from multiple
independent Prernalignant and malignant foci, manifest as hyperplasia and
metaplasia. The evolution to malignancy occurs in up to 12.5% of long term
survivors.

Ronald D. Hart,
M.D.

Sta%fr1\

III

StaI

Vitamin A derivatives called retinoids have the ability to suppress carcinogenesis and to reverse the precancerous lung lesions. In early clinical trials,
retinoids have reduced the development of second primary tumors. The pur
pose of the present trial is to confirm these findings and to assess their impact
on the survival of patients with resected early stage lung cancer.
By random selection, patients in this trial will receive tablets containing either
13-cis retinoic acid or placebo. The study will compare the incidence of sec
ond primary tUmors in the treated and control groups.
Stage II: Surgery- +/ ci
Although long term survival rates of 50 to 70% can be expected in patients
with stage I lung cancer, once local lymph nodes become involved (stage II),
the survival drops to 20 to 50%. Many of these patients have undetected
residual disease in the chest or micrometastatic disease elsewhere which
results in treatment failure. Efforts to treat the residual disease with
chemotherapy and radiation therapy have lead to a delayed recurrence and
improvement in the median survival. Recently, a new chemotherapy program of cisplatin and VP-16 has produced a high response rate of 45 % in
advanced disease, and has lead to a significant increase in survival when used
postoperatively in resected patients.
Based on this experience, the current trial will evaluate the survival of surgi
cally resected patients with stage II or limited stage lilA non-small cell lung
cancer who are treated postoperatively with radiation therapy with or without adjuvant chen-iotherapy (cisplatin and VP-16). The trial will also evalu
ate the effect of radiation therapy alone or radiation therapy and chemother
apy on the time to treatment failure, pattern of local and distant recurrence
and toxicity.
Stage lilA, Potentially Resectable.
Some patients who present with regionally advanced lung cancer have dis
ease confined to ipsjlateral mediastinal nodes and are potentially resectable.
Radiation therapy, surgery, chemotherapy and combinations of these modalities have been tried, but the best treatment for these patients is unknown,
and there is no consensus on what constitutes “standard” therapy. In an
attempt to clarify this situation, this study will randomly assign patients to
one of two treatments Half of the patients will be treated with radiation
therapy, then surgery, then further radiation therapy. The other patients will
be treated with chemotherapy then surgery, then further chemotherapy fol
lowed by radiation therapy. The trial will compare the impact of these treatments on the disease free survival and overall survival. It will also describe
the patterns of recurrence, the impact of preoperative chemotherapy and
radiation therapy on the resectability rates, and will document the toxicity
encountered with this combined approach.
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Stage lilA, Unresectable.
Approximately 20% of patients with non-small cell lung cancer present with
disease which is confined to the chest but is not resectable because of medi
astinal involvement. These patients have been treated with radiation thera
py. Long term survival is uncommon and the median survival is 6 to 12
months. Prior efforts to improve on these results by the addition of
chemotherapy has had variable success. A recently developed chemotherapy
program of cisplatin and VP-16 has lead to a high response rate in advanced
disease and when combined with radiation therapy in regionally advanced,
unresectable lung cancer, has lead to a 20% disease free survival at three
years, compared to 10% in the radiation therapy alone group. Building on
this promising result, the current trial will determine the value of adding the
radiation sensitizer carboplatin to the previous best treatment program of cis
platin and VP-16 chemotherapy followed by radiation therapy. The trial will
evaluate the rate of local disease control and impact on survival.
Stage IV: G-CSF or Ciproftoxacin
Chemotherapy is the major treatment for metastatic lung cancer. Most regi
mens cause substantial myelosuppression, often resulting in life threatening
septicemia. Two strategies have been suggested to combat this problem.
Granulocyte colony stimulating factors (G-CSF) can stimulate the prolifera
tion of granulocytes. By combining them with chemotherapy, it is possible to
circumvent the risks of myelosuppression. Another strategy is to use prophy
lactic antibiotics for selective decontamination. The goal of this trial is to
compare the benefits of using G-CSF or the prophylactic antibiotic
ciprofloxacin, or both G-CSF and ciproftoxacin in patients receiving high
dose chemotherapy for lung cancer. The study will compare the incidence
and length of febrile granulocytopenia, number of documented infections,
number of days of hospitalizations, and the effect of response, survival and
toxicity.

Ronald D. Hart, M.D.

Survival rates published in Cancer Facts &
Figures 1 991, reveal a five year survival
rate of 13% for lung cancer patients with
all stages ofdisease. This rate is also
reflected here at St. Luke’s Medical Center
(see graph below) where a five year survival
has been done ofpatients diagnosed in
1986.
-

5 YEAR SURVIVAL
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PERCENTAGE OF CASES
80

70
60
50
40
30

20

----------z

10

1

2

ALL CASES

—

LOCAL

REGIONAL

:
3

—

DISTANT
—

4

UNKNOWN

5

YEARS OF SURVIVAL
11

ThE ROLE OF RADIATION ThERAPY
The role of radiation therapy continues to evolve in the treatment of lung
cancer. In this section we will review the advances and obstacles to the treatment of this deadly disease. When I see a patient with lung cancer, the ques
tions that cross my mind include: Is the patient’s cancer curable? If so, what
are the side effects and complications of therapy? If not, is there a high
chance of the lung cancer causing suffering and disability before they die?
Can we help the patient? To answer the questions above, the patient is
staged by a history and physical, CT of the chest, abdomen and occasionally
the head, pulmonary function tests, bone scans, plain x-ray films and MRI.
William Pao,
M.D.

A treatment course is designed to be palliative or curative. The most desired
goal is to cure the patient. This is most often done with either radiotherapy
alone, or in combination with surgery, chemotherapy, lasers and photo
dynamic therapy. In patients with advanced disease, one must balance the
potential benefit versus the side effects of treatment. The control of symp
toms in many patients with terminal illness is as important as cure in patients
with early stage disease. External beam treatment is most often used. A dose
of 5000 to 6000 cGy can be delivered to the tumor and mediastinum.
Radiotherapy is the most commonly used modality in the treatment of lung
cancer. This is due to the fact that most patients are either technically or sur
gically unresectable at diagnosis. The five year survival for most stage I to III
patients treated by radiotherapy alone is in the range of 10-15 percent. This
contrasts to the 30-50 percent in patients which are surgically treated. By the
selection process, the more advanced and physiologically weaker patients are
treated by radiation therapy.
With such poor results, we are studying several innovations to improve the
local control of lung cancer. Although 50 to 70% of patients with lung cancer develop distant disease, 50% of patients who die of lung cancer, do so
due to progressive disease in the chest. Since lung cancer is so common, and
very deadly, improving the cure rate 2% is equivalent to curing all patients
who develop Hodgkin’s disease in one year.
One of these innovations is called beams-eye-view. This advance in comput
er technology allows us to see the tumor from the view point of an x-ray
beam. This achieves more accuracy in treating the known volume of tumor
in the CT or MRI image.
In conjunction with technical innovation, we have also tried to exploit the
biologic interaction of radiotherapy with chemotherapy. This is indicated in
the physiologically younger patient (less than 60 years old) with lung cancer.
Chemotherapy can be added before, concurrent with or after radiotherapy.
The most effective approach appears to be concurrent radio-chemotherapy.
This can cause complete response rates as high as 40%. In partial respon
ders, surgical resection can follow. Another method of increasing efficacy is
to give radiotherapy twice a day. This allows increased tumor cell kill and
decreases the long term effects of treatment.
The approaches outlined above apply mostly to non-small cell lung cancer.
In small-cell or oat-cell carcinomas of the lung, chemotherapy remains the
mainstay of treatment. Radiotherapy is used to consolidate any residual dis
ease in the chest. Since 40% of patients develop brain metastasis, elective
cranial irradiation is given usually to patients who have a complete or near
complete response to their chemotherapy.
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In addition to external beam radiotherapy, brachytherapy (or radioactive
implants) can be highly successful in patients with tumor in the trachea, canna or adjacent to the main-stem bronchus. The patients’ tumor need to be
within 3-4 cm. of the implant for the treatment to be effective. The most
common scenario are in the patients with locally recurrent tumors after
radiotherapy or surgery. A single 1 to 2 day application can be highly effec
tive in controlling the disease locally (Figure 1 ).

We have a long way to go before the treatment of lung cancer can be “suc
cessful.” Many of the state of the art treatment techniques are studied under
research protocols. As members of CALGB (Cancer and Leukemia group B)
and RTOG (Radiation Therapy Oncology Group), we bring the latest in
research tools to the fight in lung cancer. We urge you to help us participate
in this difficult task. We urge you to help your patients stop smoking. We
encourage you to enter your patients into clinical oncology trials.

William Pao, M.D.

(Figure 1)

.,K
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ThE SCHOOL OF RADIATION ThERAPY
The School of Radiation Therapy Technology graduated its inaugural class
in August, 1992.
For the individual students, Graduation Day marked the completion of 12
months -df intensive study.

Pam Kresl, RRT

For St. Luke’s Medical Center, graduating 4 students marked the fulfillment
of a dream of the radiation oncology department to help address the critical
shortage of radiation therapists that threatens cancer treatment centers everywhere. At its inception, we knew this year-long certification program would
train therapists with the highly developed skills necessary to administer radia
tion treatments. The comprehensive program involved studies in math,
physics, radiobiology, pathology, oncology, ethics, anatomy and physiology,
radiation protection, and nursing. The students were engaged in extensive
clinical experiences aimed at developing not only the technical skills required
by this demanding, specialized field, but also the compassionate, caring
approach to treatment we owe our patients.
All indications are that our efforts have been a resounding success. Our first
4 graduates are currently employed at St. Luke’s Medical Center and at other
treatment centers in Wisconsin. Furthermore, the skills demonstrated by the
graduates who remain with us auger well for the future of the program and
the next class of 4 students now in training.
Our success would not have been possible, however, without the wealth of
expertise we are fortunate to have here at St. Luke’s Medical Center in
Radiation Oncology and among other staff, and of course, the invaluable
hands-on training available with the state-of-the-art equipment at our dispos
al. All these factors are essential to the stimulating and rewarding learning
environment we have successfully created.
In the coming year, the School of Radiation Therapy Technology will contin
ue to uphold this standard of quality education while developing yet another
tradition of health care excellence at St. Luke’s Medical Center in which we
all can take great pride.

Pam Kresl, RRT
Educational Coordinator
School of Radiation Therapy Technology
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VINCE LOMBARDI CANCER CLINIC UPDATE
The Vince Lombardi Cancer Clinic provides state of the art chemotherapy,
immunotherapy and supportive care to patients with cancer. With the support of the Vince Lombardi Memorial Classic funds, the staff offers cancer
prevention education, early detection screenings, counseling and support ser
vices.
The Vince Lombardi Cancer Hotline receives calls from across the United
States regarding information about the latest approaches and treatment of
specific cancers. These calls come from health professionals, patients, family
members and interested consumers.
Cancer Research is a major commitment of the Vince Lombardi Cancer
Clinic.

Marija Bjegovich,
RN, BSN

In 1991 four research studies were undertaken:
-

Assessment of Hope in the Adult Cancer Patient

-

Smoking Cessation Training for House Officers

-

-

A Dose Escalation Trial of 5FU, Leucovorin and Sandostatin
for Advanced Metastatic Colorectal Cancer
A Test of the Smoke-Free Madres Smoking Cessation
Intervention

The Vince Lombardi Cancer Clinic staff supports the Autologous Bone
Marrow Transplantation and Immunotherapy Programs by coordinating and
performing all of the pheresis procedures. The pheresis program continues to
grow in 1992 as we expand our services to include coordination of plasmapheresis for patients requiring treatment for such diseases as myasthenia
gravis or guillian barre. The clinic staff continues to work towards making
cancer a preventable and controllable disease in 1992. We will continue to
have a prominent role in the medical community as a leader in cancer care.

Marija Bjegovich, RN, BSN
Supervisor, Vince Lombardi
Cancer Clinic
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FAMILIES GAiNING THE EDGE OVER CANCER
----

on November 20, 1991, the St. Luke’s Medical Center Cancer Program and
Vince Lombardi Cancer Clinic presented a public lecture about familial
cancers. Our guest speaker was Matthew Lubin, M.D., Director of Medical
Genetics at the Strang Cancer Prevention Center, New York, New York.
Dr. Lubin’s presentation focused on genetically linked cancers, their
prevention and early detection. Along with Dr. Lubin, Joy O’Connell, the
former Mrs. Brian Piccolo (Chicago Bears football star) shared her family’s
experience with cancer. Participants in the event received a free Cancer Risk
Q uestionnaire, which was evaluated by the professional staff at the Vince
Lombardi Cancer Clinic.
Nancy A. Nowak

The lecture was the kick-off for a year long focus on cancer prevention,
detection and screening. During the year, public lectures and screening
programs were offered for prostate, breast, skin, colorectal, ovarian and
cervical cancers. Over 2,000 individuals participated in the lectures and
screenings, which helped the community gain an awareness of cancer
prevention and ea rly detection.

Nancy A. Nowak
Cancer Program Director
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PROSTATE SCREENINGS
St. Luke’s Medical Center had participated in the Annual Prostate Awareness
Week in 1990 and community interest in the prostate screenings at that time
was high. Dr. Stuart Fine, a urologist on staff, was particularly interested in
bringing to the men in the Milwaukee community on ongoing screening program for prostate cancer.
In June of 1991, a media campaign was launched to publicize a trial prostate
screening program. The response was overwhelming and what was envi
sioned as a periodic screening offering became a monthly endeavor. Funding
for the ongoing Prostate screening program is provided by the Vince
Lombardi Memorial Classic.
Individuals who participate in the Screening Program have a Prostate Specific
Antigen (PSA) drawn and a Digital Rectal Examination (DRE) performed by
a urologist. Men with abnormal DRE’s or elevated PSA’s are referred to
their physicians for follow-up. There were 397 men screened in the initial
screenings in June, July and August of 1991. Of the men screened, 115 men
were found to have an abnormal DRE and 56 were found to have an elevat
ed PSA. An additional 144 were screened during the 1991 Prostate Cancer
Awareness Week in September. In October and November, an additional
102 men were screened, totaling 659 men screened for prostate cancer in
1991. Of those screened in 1991, 131 abnormal DRE’s were found and 76
PSA’s were elevated. Prostate cancer was detected during follow-up in 6
men.

Kerry A. Twite,
RN, MSN, OCN

Since its inception, the prostate screening program has met with favorable
response from those who have been screened and those urologists who have
shared their time and expertise.

Kerry A. Twite, RN, MSN, OCN
Clinical Nurse Specialist Oncology
Vince Lombardi Cancer Clinic
-
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OVARIAN CANCER SUPPPORI GROUP
In April 1991, Gene Wilder recounted his wife, comedienne, Gilda
Radner’s
struggle with ovarian cancer at a public presentation at the Pfister
Hotel.
Several women in the audience spoke of the need for a support group
for
women with ovarian cancer. That June the first organizational meetin
g for
the Ovarian Cancer support group was held. Over 40 individuals,
both
patients and their family members attended. Those present heard
women shared of their diagnosis and treatment for ovarian cancer the stories
.
members voiced their concerns about the familial link in ovarian Family
cancer
. It
was evident from that first night, that women fighting ovarian
cancer had
some powerful feelings and experiences to share.
The Ovarian Cancer Support Group meets monthly on the first
evening from 6:30 P.M. to 8:00 P.M. The group averages aboutTuesday
6-8 individ
uals.
Some common threads are heard in each woman’s telling of her
with this deadly disease. Symptoms are often vague and insidio experience
us
easily set aside by the woman herself. If she seeks medical help, and are
the
too may be easily fooled by tests that don’t show anything wrong physician
and vague
complaints such as overwhelming fatigue.
Commonly women have shared that diagnosis often takes month
to many and different doctors. Some have been sent to a psychi s, with trips
find out later that they have cancer. These women voice much atrist, only to
frustration
and anger, that despite attempts to get diagnosed or going
to their physician
at the first symptom, they were still diagnosed at a late stage.
Finally having reached a diagnosis that “something is wrong
”,
bers express guilt at minimizing the woman’s symptoms. Spousefamily mem
at a disease that can potentially take away their most preciou s feel anger
s
especially if the diagnostic period was lengthy. Sharing with relationship,
others who tell
the same story is therapeutic cleansing, energizing, dissipa
ting anger,
bonding together in “a mission”.
These women are militant about women being informed
about the signs and
symptoms of ovarian cancer, the risks, familial tendency,
and
rent diagnostic tests. They spread the word to their female the most curfamily members,
their physicians, neighbors and friends. Their intent is to spare
anguish they have had to endure as a result of lengthy diagno others the
sis.
—

Kerry A. Twite, RN, MSN, OCN
Clinical Nurse Specialist Oncology
Vince Lombardi Cancer Clinic
-
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Though, at times, some individuals found “not seeking out
OK, the maiority suggested that coping was enhanced by information” as
searching the litera
ture, getting a second opinion, and exploring all treatment
options. This was
particularly true if standard treatment had become ineffec
tive. Several of the
women have participated in clinical trials from ABMR to
Taxol.
These brave women speak of looking good but feeling devast
ated and violat
ed by the volume of tests and treatments. “I never though
t I’d cope with it,
but I do”, “I still never know if I’ll cope with another treatm
ent regime”,
“Maybe this will be the one I’ll say no to, I can’t do it,
but I do.” It’s often a
fine line between being treated as only a person but having
others not minimize the toll the disease and treatment take.
Remission is a time of joy, though fear of recurrence
often surfaces as an ever
present worry. “Time goes slow on chemotherapy:
I mark time and worry
that this is my last Christmas, but then it comes, and
I worry about spring.”
The support group has offered to those women
in need a place to share their
common concerns and to draw on the strengt
hs of the group to help each
individual cope with the experience of ovarian
cancer.

“WHAT DO YOU TELL THE CHLDRFN?”
Cancer touches the lives of one in four American families. When children are
touched by cancer, every aspect of their lives is affected including their performance in school. In an effort to meet the needs of these children, St.
Luke’s Medical Center, Children’s Hospital of Wisconsin and the American
Cancer Society sponsored a program, called “What Do You Tell The
Children”, for elementary school teachers. This half-day program provided
important insights to assist teachers as they try to help children cope when
someone in their family or a classmate is living with cancer.
-

The program included information about cancer prevention, detection and
treatment, psychosocial issues of children experiencing cancer, and strategies
to help students understand when a classmate has cancer. The American
Cancer Society provided an overview of free teaching aides that are available
to elementary school teachers.

Terry Ann
Tingwald, RN,
BSN, NC

This program was attended by approximately 50 teachers and principals and
received favorable review in the Milwaukee Journal. Comments included,
“As a child of a cancer patient and a mother of three year old twins, I found
the information presented very useful and helpful as well as comforting and
hopeful” and “A great help! Wish all teachers could have been there to share
this educational experience with us.”
St. Luke’s Medical Center and the Vince Lombardi Cancer Clinic continue to
promote The Kids’ Connection, a support group to help children cope when
a parent has cancer and grief support group for young children and teenagers
who are grieving the death of a parent or grandparent. If you would like further information, please contact the Vince Lombardi Cancer Clinic Hotline
at 649-7200.

Terry Ann Tingwald, RN, BSN, NC
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V1SNG NURSES ASSOCIATION HOSPICE
The VNA (Visiting Nurses Association) Community Hospice will mark its•
third year of service to the community in November of 1992. A program of
the Visiting Nurses Association, the hospice was established in 1989 in conjunction with St. Luke’s Medical Center. The program has provided hospice
care to approximately 750 patients and families in the greater Milwaukee
area.
/

Katherine Kalmer,
RN, BSN

Hospice care is available to the terminally ill person who no longer wishes to
receive active treatment for their disease. The goals of the care the patient
receives are to keep the person comfortably at home and to maximize the
quality of the remainder of the person’s life. A multidisciplinary team which
includes physicians, nurses, social workers, chaplains, therapists, aides, vol
unteers, family, as well as the patient work together to provide psychological
and spiritual support and most importantly, symptom control in the home
setting. The VNA Community Hospice has been able to provide 95% of
that care at home, although respite and inpatient care are available if needed.
An important element of the hospice program is bereavement follow-up and
support for the survivors. This continuity of service can be very helpful in
reconciling grief. Bereavement follow-up is on-going for one year following
the death of a patient.
Interest in the hospice concept with its emphasis on death with dignity and
caring is growing. Hospice care is now a recognized alternative to traditional
hospital care for terminally ill patients.

Katherine Kalmer, RN, BSN
Assistant Manager of VNA Community Hospice
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GLOSSARY
Analytic Cases: Cases which are first diagnosed and/or given their first course
of treatment at St. Luke’s Medical Center
Autocñne Factors: A growth factor produced by the cell
Benign: A term for a tumor that does not normally threaten a person’s life
t that is, a tumor that is not cancerous and does not attack).
Brachytherapy: The use of implants of radioactive materials such as radium,
cesium, iridium, or gold at the site of cancer
Bronchoscopy: The examination of the bronchi with a bronchoscope
Cancer: A tumor that attacks and poses a serious threat to a person’s life
Carcinogenic Agents: Cancer producing substances
Chemotherapy: Treatment with powerful drugs that attack cancer cells
Combined Therapy: Refers to any combination of surgery, radiation,
chemotherapy, hormone therapy or other therapy administered jointly as a
single course of treatment
Diagnostic Only: Cancer related treatment was not given; this may occur for
many reasons; for example, the patient refused treatment, or the patient’s
general condition is unsatisfactory for treatment
Distant Stage: A neoplasm that has spread to other organs or lymph nodes
from the primary tumor.
Endoscope: A device consisting of a tube and optical system for observing the
inside of a hollow organ or cavity
Epidemiology: The study of epidemics and epidemic diseases
External Radiation Therapy: Radiation therapy that uses rays from a
machine
First Course of Treatment: The tumor directed treatments started within the
first four months after diagnosis
Histology: The study of cells and microscopic tissues
In situ: A tumor classified microscopically as in situ, non-invasive, pre-inva
sive, non-infiltrating, intraductal, intraepithelial or intraepidermal
Lobectomy: The surgical removal of a lobe from any organ or gland
Local Stage: Tumor restricted to the organ of origin, but may be invasive or
infiltrating within the organ of origin
Lymph: A nearly clear fluid collected from tissues around the body and
returned to the blood via the lymphatic system
Lymph Nodes: Small bean-shaped structures scattered along the vessels of
the lymphatic system. The nodes filter bacteria and cancer cells that may
travel through the system
Malignant: A term for a tumor that can threaten a person’s life; that is, a
tumor that is cancerous. Malignant has the same meaning as cancerous
Metastasis: The spread of cancer from its original site to distant areas. The
cancer cells are carried to distant sites by blood and lymph
Non-Analytical Cases: Cases which are seen at St. Luke’s Medical Center
after the first course of treatment
21

Oncologist: A physician who specialized in
treating cancer
Pheresis: A procedure to remove blood from
an individual in order to sepa
rate certain elements, such as platelets or
red blood cells and reintroducing
the remaining components into the pati
ent
Pulmonary Function Tests: Tests used
to determine the ability of the lungs to
exchange oxygen and carbon dioxide.
The
suring the maximum amount of air that se tests are usually done by mea
can be exhaled after inhaling and the
time required for that expiration
Radiation Therapy: Treatment wit
h high-energy radiation from x-rays or
other sources of radiation
Regional Stage: A tumor that has exte
nded beyond the limits of the organ of
origin into 1 ) surrounding organs or
tissues by direct extension, 2) regional
lymph nodes by metastasis, or 3) a com
bination of 1 and 2 and appears to
have spread no further
Recurrence: The return of cancer afte
r a disease-free interval
Stage: A term used to describe the size
and extent of spread of the cancer
Staging: Tests conducted to determi
ne the stage of cancer
Surgery: The partial or total removal
of the tumor excluding a biopsy
Thoracoscopy: A diagnostic examin
ation of the pleural cavity with an end
o
scope
Thoracotomy: A surgical incision of
the chest wall

REFERENCES
Cancer Facts & Figures 1991, Am
erican Cancer Society, Inc., Georgia.
Cancer Facts & Figures 1986, Am
erican Cancer Society, Inc., Georgia
.
Summary Staging Guide, SEER (Sur
veillance, Epidemiology and End Resu
lts)
Program, US Department of Health
and Human Services, National Inst
itute
of Health, Publication No. (NIH)
86-2316, April 1977.
Cancer Program Manual, Americ
an College of Surgeon’s Commission
on
Cancer, 1991.
-

-
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Manual for Staging of Cancer, Thi
rd Edition, American Joint Commit
Cancer, J.B. Lippincott CO., Phi
tee on
ladelphia, 198$.
Ca-A Cancer Journal for Clinician
s, January/February 1991, Annual
Statistics Issue, American Can
cer Society, Inc., Vol. 41, No. 1.
Ca-A Cancer Journal for Clin
icians, May/June 1991, Lung Can
Smoking, American Cancer
cer &
Society, Inc., Vol. 41, No. 3.
Lung Cancer: Current Con
cep
Publication, American Cancer ts and Prospects, Professional Education
Society, Inc., 1983.

Le

3

)

;t:

‘t’t
.-

:b
-*

4

.

*

‘

.z
:

‘%

:
.

:

•

..

,

.‘./

..

..‘.

.

I
•

k

—

1

I

.

a

,

%&

Wa

JZz
4m
L1.i .

,

.

%

..‘

.

..‘

.
,.,

.

:•

....

i.

•

S..:

•

••

.
,,S

2900 West Oklahoma Avenu
. e
0.Box29o;
M1lwauke, Wsco1 53201 2901

ca1Cet

StLukeMeth

,•

HealthCafe

•

•

.

S

•

,.

:

,

:

.
,.

-

,

:

::

.,

S

.

,

.

.

.

1991 CANCER ANNUAL REPORT SUPPLEMENT
CANCER REGISTRY REPORT
In 1991, 1,440 new patients were accessioned into the St. Luke’s Medical
Center Cancer Regzst 1 268 analytic 1 72 non analytic The Cancer
Registry now includes over 18 000 patientc with a 98% follow up rate We
have welcomed and appreciated the opportunz to retrieve over 2 0 requests
and inquiries for data to be used in special studies, audits, and research by
medical staff, administration and marketing. In the past year we have partic
ipated in a Long/Short Term Patient Care Evaluation Study for Cervical
Cancer as well as hospital based Quality Assurance studies ofsoft Tissue
Sarcomas and Cervical Cancer. The graphs and charts comprising the 1991
Cancer Program Annual Report will present a brief overview of cancer diag
nosis and treatment at St. Luke’s Medical Center. If there are any questions
or inquiries for further information, they may be directed to the Cancer
Registry staffat 649-6720.

Sandy Blixt, R.R.A.
Cancer Registrar
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1991 CANCER ANNUAL REPORT SUPPLEMENT
This primary site distribution presents
breast cancer as the most frequently
diagnosed cancer site in 1 991 at St.
Luke’s Medical Center. The second
most frequent site of cancer, skin cancer,
includes all basal cell and squamous cell
carcinomas as well as melanomas.
Lung cancer continues to be one of the
top five cancer sites diagnosed and treated here at St. Luke’s. More details
regarding lung cancer are available
throughout this annual report or by
contacting the Cancer Registry.

1991 SITE DISTRIBUTION
SITE
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This age distribution presents the age
group ofSS to 84 as the largest percentage ofaccessioned population at St.
Luke’s Medical Center. These patients
from ages 55 to 84 make up 79% of the
total number of new cases for 1 991.
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1991 CANCER ANNUAl REPORT SUPPLEMENT
Number of Cases

Percent

1991 GENERAL SUMMARY STAGE
FOR ALL SITES
,

Insitu

71

5%

Local

646

45%

Regional

378

26%

Distant

292

20%

53

4%

Unknown

DISTANT 20%

1440

UNKNOWN 4%’

REGIONAL 26%

1991 GENERAL SUMMARY STAGE
FOR TOP 5 SITES
Number of Cases

Percent

Insitu

25

11%

Local

116

51%

Regional

70

31%

Distant
Unknown

9

4%

6

3%

BREAST (226 patients)
LOCAL 51%

UNKNOWN 3%

226
INSITU 11%”

DISTANT 4%

1991 CANCER ANNUAL REPORT SUPPLEMENT
SKIN (1 87 patients)

Number of Cases

Percent

In situ

17

_J /0

Local

155

83%

Regional

4

) 0/
L /0

Distant

5

a2 0/
/0

Unknown

6

2 0/
3 /0

LOCAL 83%

REGIONAL 2%

a oi

DISTANT 3%

187

INSITU 9%

UNKNOWN 3%

LUNG (1 77 patients)

Number of Cases

Percent

In situ

0

noi
V /0

Local

42

24%

Regional

64

36%

Distant

67

38%

Unknown

4

) 0/
/0

LOCAL 24%

UNKNOWN 2%,4

DISTANT 38%

177
REGIONAL 36%

1991 CANCER ANNUAL REPORT SUPPLEMFNT
Number of Cases

Percent

In situ

0

0/
r
V /0

Local

96

60%

Regional

34

21%

Distant

25

16%

Unknown

4

2 0/
3 /0

PROSTATE (159 patients)
LOCAL 60%

159
UNKNOWN 3%’
DISTANT 16%
REGIONAL 21%
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PRESENTA11ONS AND INSTRUCTIONAL SESSIONS
Nursing

Autologous Peripheral Stem Cells: Collection and Reinfusion, Pamela
Schroeder, RN, St. Luke’s Medical Center
IL-2[FIL Therapy: A Clinical Overview, Carla Rohloff, BSN, OCN, St.
Luke’s Medical Center
IL-2 Therapy: The Challenge of Patient Education, Melissa Michalak, BSN,
Carla Rohloff, BSN, OCN, St. Luke’s Medical Center
The Kids Connection: A Support Group to Help Children Cope When a
Parent Has Cancer, Virginia Bourne, MSN, RN, CNS, Milwaukee, WI
“Beyond the Bedside: Making the Transition into Nontraditional Roles”,
Kathy Oldham, RN, BSN
“Photodynamic Therapy Issues for Managers: Budget and Reimbursement”,
Angela D. Klimaszewski, MSN, RN, OCN
“Medicus: One Year of Experience With the Indicators on the Six-Category
Tool”, Angela D. Klimaszewski, MSN, RN, OCN
Clinical Controversies and Future Frontiers in Bone Marrow
Transplantation, Kathy Oldham, RN, BSN
“New Graduates are an Asset to the Inpatient Oncology Unit: Perceptions of
a Preceptor”, Barbara Ritter, RN, BSN, OCN
“Charting by Exception: a Cost-Effective and Efficient Approach to
Documentation in the Ambulatory Oncology Setting”, Marija Barthel, RN,
BSN
“Psychosocial Adjustment After Bone Marrow Transplant for Patients,
Families, and the Community: Resuming Pretransplant Roles Kathy
Oldham, RN, BSN
“,

SI. LUKE’S CANCER CONFERENCES
Tumor Board Conference
Conferences were held on the second and fourth Mondays ofevery month at
noon. They were patient oriented, multi-disciplinary cancer conferences with
an average attendance of3O. For more information or any questions, please
call 649-6720.

Head and Neck Tumor Conference
Conferences were held on the first and third Mondays ofevery month at
noon. They were held to discuss selected difficult head and neck tumors from
a multi-disciplinary approach. For more information or any questions, please
call 649-3900.

Security Bank Cancer Lectureship Series 1991
February 28, 1 991

WHAT IF CURE IS NO LONGER POSSIBLE?
Josefina Magno, M.D.
President, International Hospice Instute
Director, Hospice Education, Research &
Development
Henry Ford Hospital
Detroit, MI

September 26, 1 991

INTRAOPERATIVE RADIATION THERAPYPRACTICAL APPLICATIONS IN 1991
R. Dirk Noyes, M.D.
Clinical Associate Professor
Department of Surgery
University of Utah
Salt Lake City, UT

November 21, 1991

INHERITED SUSCEPTIBILITY TO CANCER
Matthew B. Lubin, M.D.
Director ofMedical Genetics
Strang Cancer Prevention Center
New York, NY

Schroeder Fellowship Program In Clinical Oncology Programs 1991
March 12, 1991

LILLIANNAIL, Ph.D., R.N.
Assoc. Dean of Research
University of Utah School of Nursing
Salt Lake City, UT
-

May 28, 1991

EDWARD G. SCHNEIDER, Ph.D.
Professor of Physiology
University of Tennessee
Memphis, TN

May30, 1991

HAJIMEFUCHIHATA,M.D.
Professor & Chairman of Dentistry
Osaka University
Osaka, Japan

July 18, 1991

LETHA MILLS, M.D.
Assistant Professor
Dartmouth Hitchcock Medical Center
Hanover, NH

August 2, 1991

R. JEROME LANDRENEAU, M.D.
Assistant Professor of Surgery
University of Pittsburgh
Section of Thoracic Surgery
Pittsburgh, PA

